Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

Jian Qiao, Hongxun Wang, Timothy Kottke, Christine White, Katie Twigger, Rosa Maria Diaz, Jill Thompson, Peter Selby, Johann De Bono, Alan Melcher, Hardev Pandha, Matt Coffey, Richard Vile, Kevin Harrington

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumorald elivery and replication of i.v. injected virus. Experimental Design: I.v. delivery of reovirus was combined with different regimens of i.p. administered cyclophosphamide in C57Bl/6 mice bearing established s.c. B16 tumors. Intratumoralviral replication, tumor size, and survival were measured along with levels of neutralizing antibody (NAb) in the blood. Finally, differential toxicities of the virus/cyclophosphamide regimens were monitored through viral replication in systemic organs, survival, and cardiac damage. Results: Repeated i.v. injection of reovirus was poorly effective at seeding intratumoral viral replication/oncolysis. However, by combining i.v. virus with cyclophosphamide, viral titers of between 10 7 and 108 plaque-forming units per milligram were recovered from regressing tumors. Doses of cyclophosphamide that ablated NAb were associated with severe toxicities, characterized by viral replication in systemic organs - toxicities that are mirrored by repeated reovirus injections into B-cell knockout mice. Next, we restructured the dosing of cyclophosphamide and i.v. virus such that a dose of 3 mg cyclophosphamide was administered 24 h before reovirus injection, and this schedule was repeated every 6 days. Using this protocol, high levels of intratumoral viral access and replication (∼107 plaque-forming units per milligram tumor) were maintained along with systemically protective levels of NAb and only very mild, non - life-threatening toxicity. Conclusion: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity. These data support the use of cyclophosphamide to modulate, but not ablate, patient NAb, in development of carefully controlled clinical trials of the systemic administration of oncolytic viruses.

Original languageEnglish (US)
Pages (from-to)259-269
Number of pages11
JournalClinical Cancer Research
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Cyclophosphamide
Neutralizing Antibodies
Viruses
Neoplasms
Oncolytic Viruses
Injections
Tissue Survival
Controlled Clinical Trials
Knockout Mice
Appointments and Schedules
B-Lymphocytes
Research Design
Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. / Qiao, Jian; Wang, Hongxun; Kottke, Timothy; White, Christine; Twigger, Katie; Diaz, Rosa Maria; Thompson, Jill; Selby, Peter; De Bono, Johann; Melcher, Alan; Pandha, Hardev; Coffey, Matt; Vile, Richard; Harrington, Kevin.

In: Clinical Cancer Research, Vol. 14, No. 1, 01.01.2008, p. 259-269.

Research output: Contribution to journalArticle

Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM, Thompson, J, Selby, P, De Bono, J, Melcher, A, Pandha, H, Coffey, M, Vile, R & Harrington, K 2008, 'Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus', Clinical Cancer Research, vol. 14, no. 1, pp. 259-269. https://doi.org/10.1158/1078-0432.CCR-07-1510
Qiao, Jian ; Wang, Hongxun ; Kottke, Timothy ; White, Christine ; Twigger, Katie ; Diaz, Rosa Maria ; Thompson, Jill ; Selby, Peter ; De Bono, Johann ; Melcher, Alan ; Pandha, Hardev ; Coffey, Matt ; Vile, Richard ; Harrington, Kevin. / Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 1. pp. 259-269.
@article{abbfdc67e3bf481aacffb3286bbd22eb,
title = "Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus",
abstract = "Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumorald elivery and replication of i.v. injected virus. Experimental Design: I.v. delivery of reovirus was combined with different regimens of i.p. administered cyclophosphamide in C57Bl/6 mice bearing established s.c. B16 tumors. Intratumoralviral replication, tumor size, and survival were measured along with levels of neutralizing antibody (NAb) in the blood. Finally, differential toxicities of the virus/cyclophosphamide regimens were monitored through viral replication in systemic organs, survival, and cardiac damage. Results: Repeated i.v. injection of reovirus was poorly effective at seeding intratumoral viral replication/oncolysis. However, by combining i.v. virus with cyclophosphamide, viral titers of between 10 7 and 108 plaque-forming units per milligram were recovered from regressing tumors. Doses of cyclophosphamide that ablated NAb were associated with severe toxicities, characterized by viral replication in systemic organs - toxicities that are mirrored by repeated reovirus injections into B-cell knockout mice. Next, we restructured the dosing of cyclophosphamide and i.v. virus such that a dose of 3 mg cyclophosphamide was administered 24 h before reovirus injection, and this schedule was repeated every 6 days. Using this protocol, high levels of intratumoral viral access and replication (∼107 plaque-forming units per milligram tumor) were maintained along with systemically protective levels of NAb and only very mild, non - life-threatening toxicity. Conclusion: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity. These data support the use of cyclophosphamide to modulate, but not ablate, patient NAb, in development of carefully controlled clinical trials of the systemic administration of oncolytic viruses.",
author = "Jian Qiao and Hongxun Wang and Timothy Kottke and Christine White and Katie Twigger and Diaz, {Rosa Maria} and Jill Thompson and Peter Selby and {De Bono}, Johann and Alan Melcher and Hardev Pandha and Matt Coffey and Richard Vile and Kevin Harrington",
year = "2008",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1510",
language = "English (US)",
volume = "14",
pages = "259--269",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

AU - Qiao, Jian

AU - Wang, Hongxun

AU - Kottke, Timothy

AU - White, Christine

AU - Twigger, Katie

AU - Diaz, Rosa Maria

AU - Thompson, Jill

AU - Selby, Peter

AU - De Bono, Johann

AU - Melcher, Alan

AU - Pandha, Hardev

AU - Coffey, Matt

AU - Vile, Richard

AU - Harrington, Kevin

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumorald elivery and replication of i.v. injected virus. Experimental Design: I.v. delivery of reovirus was combined with different regimens of i.p. administered cyclophosphamide in C57Bl/6 mice bearing established s.c. B16 tumors. Intratumoralviral replication, tumor size, and survival were measured along with levels of neutralizing antibody (NAb) in the blood. Finally, differential toxicities of the virus/cyclophosphamide regimens were monitored through viral replication in systemic organs, survival, and cardiac damage. Results: Repeated i.v. injection of reovirus was poorly effective at seeding intratumoral viral replication/oncolysis. However, by combining i.v. virus with cyclophosphamide, viral titers of between 10 7 and 108 plaque-forming units per milligram were recovered from regressing tumors. Doses of cyclophosphamide that ablated NAb were associated with severe toxicities, characterized by viral replication in systemic organs - toxicities that are mirrored by repeated reovirus injections into B-cell knockout mice. Next, we restructured the dosing of cyclophosphamide and i.v. virus such that a dose of 3 mg cyclophosphamide was administered 24 h before reovirus injection, and this schedule was repeated every 6 days. Using this protocol, high levels of intratumoral viral access and replication (∼107 plaque-forming units per milligram tumor) were maintained along with systemically protective levels of NAb and only very mild, non - life-threatening toxicity. Conclusion: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity. These data support the use of cyclophosphamide to modulate, but not ablate, patient NAb, in development of carefully controlled clinical trials of the systemic administration of oncolytic viruses.

AB - Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumorald elivery and replication of i.v. injected virus. Experimental Design: I.v. delivery of reovirus was combined with different regimens of i.p. administered cyclophosphamide in C57Bl/6 mice bearing established s.c. B16 tumors. Intratumoralviral replication, tumor size, and survival were measured along with levels of neutralizing antibody (NAb) in the blood. Finally, differential toxicities of the virus/cyclophosphamide regimens were monitored through viral replication in systemic organs, survival, and cardiac damage. Results: Repeated i.v. injection of reovirus was poorly effective at seeding intratumoral viral replication/oncolysis. However, by combining i.v. virus with cyclophosphamide, viral titers of between 10 7 and 108 plaque-forming units per milligram were recovered from regressing tumors. Doses of cyclophosphamide that ablated NAb were associated with severe toxicities, characterized by viral replication in systemic organs - toxicities that are mirrored by repeated reovirus injections into B-cell knockout mice. Next, we restructured the dosing of cyclophosphamide and i.v. virus such that a dose of 3 mg cyclophosphamide was administered 24 h before reovirus injection, and this schedule was repeated every 6 days. Using this protocol, high levels of intratumoral viral access and replication (∼107 plaque-forming units per milligram tumor) were maintained along with systemically protective levels of NAb and only very mild, non - life-threatening toxicity. Conclusion: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity. These data support the use of cyclophosphamide to modulate, but not ablate, patient NAb, in development of carefully controlled clinical trials of the systemic administration of oncolytic viruses.

UR - http://www.scopus.com/inward/record.url?scp=40749090005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749090005&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1510

DO - 10.1158/1078-0432.CCR-07-1510

M3 - Article

C2 - 18172278

AN - SCOPUS:40749090005

VL - 14

SP - 259

EP - 269

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -